Bio-heart's IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System
Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

IASO-Bio's Fucaso Wins Hong-Kong Approval as First China CAR-T
CompanyDrug

IASO-Bio’s Fucaso Wins Hong-Kong Approval as First China CAR-T

BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma
CompanyDrug

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development
CompanyDeals

Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development

Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program
CompanyDeals

Innova Therapeutics Acquires Enci Therapeutics’ IVT-8086 Cancer Program

Gene Key's iNKT Cell Therapy Wins NMPA Nod for ARDS, First Allogeneic Ready-to-Use
CompanyDrug

Gene Key’s iNKT Cell Therapy Wins NMPA Nod for ARDS, First Allogeneic Ready-to-Use

SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect
CompanyDrug

SciClone’s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect

Novartis' Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria
CompanyDrug

Novartis’ Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria

CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%
Policy / Regulatory

CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%

Hengrui's Three Oncology Assets Win NMPA Clinical Trial Approval
CompanyDrug

Hengrui’s Three Oncology Assets Win NMPA Clinical Trial Approval

Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential
CompanyDrug

Humanwell’s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential

Innovent's mazdutide 9mg Obesity Application Accepted by NMPA
CompanyDrug

Innovent’s mazdutide 9mg Obesity Application Accepted by NMPA